Kazia Therapeutics Faces Nasdaq Listing Deficiency
Ticker: KZIA · Form: 6-K · Filed: May 23, 2024 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-deficiency, compliance, sec-filing
TL;DR
Nasdaq sent Kazia a deficiency notice, they're trying to fix it.
AI Summary
Kazia Therapeutics Limited received a deficiency notification from Nasdaq on November 20, 2023, regarding its non-compliance with listing requirements. The company is currently working to regain compliance.
Why It Matters
This notification indicates potential delisting from Nasdaq, which could significantly impact the company's liquidity, investor confidence, and ability to raise capital.
Risk Assessment
Risk Level: medium — The deficiency notification from Nasdaq poses a risk of delisting, which could negatively affect the company's stock value and access to capital markets.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Nasdaq Stock Market LLC (company) — Listing Qualifications Staff
- November 20, 2023 (date) — Date of deficiency notification
FAQ
What was the specific reason for the Nasdaq deficiency notification?
The filing states the company received a deficiency notification from Nasdaq's Listing Qualifications Staff but does not specify the exact reason within this excerpt.
When did Kazia Therapeutics receive the deficiency notification?
Kazia Therapeutics received the deficiency notification on November 20, 2023.
What is Kazia Therapeutics' primary business?
Kazia Therapeutics Limited is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the company's principal executive office address?
The company's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Is Kazia Therapeutics required to file Form 20-F?
Yes, the filing indicates that Kazia Therapeutics files or will file annual reports under cover of Form 20-F.
Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 18.3 · Accepted 2024-05-23 07:00:28
Key Financial Figures
- $1.00 — ce of the Companys security is at least $1.00 per share for a minimum of 10 consecuti
Filing Documents
- d841218d6k.htm (6-K) — 12KB
- 0001193125-24-145419.txt ( ) — 14KB
Forward-Looking Statements
Forward-Looking Statements This Report on Form 6-K may contain forward-looking statements, which can generally be identified as such by the use of words such as may, will, estimate, future, forward, anticipate, or other similar words. Any statement describing Kazias future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding Kazias intentions with respect to regaining compliance with the Minimum Bid Price Requirement, including effecting a ratio change of the ADSs to its ordinary shares, if necessary. Such statements are based on Kazias current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties related to the possibility that Kazia may not regain compliance with the Minimum Bid Price Requirement. These and other risks and uncertainties are described more fully in Kazias Annual Report, filed on form 20-F with the United States Securities and Exchange Commission (the SEC ), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Report on Form 6-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 23 May 2024